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1078–5884/00Venous Leg Ulcer: A Meta-analysis of Adjunctive Therapy
with Micronized Purified Flavonoid Fraction
P. Coleridge-Smith,1 C. Lok2* and A.-A. Ramelet31Department of Surgery, UCL Medical School, The Middlesex Hospital, London WIN 8AA, UK; 2CHU,
Service de Dermatologie, Hopital Sud, 80054 Amiens Cedex 1, France; and 32 Place Benjamin Constant,
1003 Lausanne, SwitzerlandObjective. To assess the effect of oral treatment with micronized purified flavonoid fraction (MPFF) on leg ulcer healing.
Design. Meta-analysis of randomised prospective studies using MPFF in addition to conventional treatment.
Materials and methods. Five prospective, randomised, controlled studies in which 723 patients with venous ulcers were
treated between 1996 and 2001 were identified. Conventional treatment (compression and local care) in addition to MPFF
was compared to conventional treatment plus placebo in two studies (NZ309), or with conventional treatment alone in
three studies (NZ414). The primary end point was complete ulcer healing at 6 months.
Results. At 6 months, the chance of healing ulcer was 32% better in patients treated with adjunctive MPFF than in those
managed by conventional therapy alone (RRR: 32%; CI, 3–70%). This difference was present from month 2 (RRR: 44%; CI,
7–94%), and was associated with a shorter time to healing (16 versus 21 weeks; PZ0.0034). The main benefit of MPFF was
present in the subgroup of ulcers between 5 and 10 cm2 in area (RRR: 40%; CI, 6–87%), and those present for 6–12 months
duration (RRR: 44%; CI, 6–97%).
Conclusion. These results confirm that venous ulcer healing is accelerated by MPFF treatment. MPFF might be a useful
adjunct to conventional therapy in large and long standing ulcers.Keywords: Bandages; Compression therapy; Varicose ulcer; Meta-analysis; Flavonoids; Micronized purified flavonoid
fraction (MPFF).Introduction
Leg ulcers are mostly of venous origin.1 The standard
of care for venous leg ulcers is based on local wound
care and application of compression therapy.2 Pub-
lished rates of healing utilizing this standard of care
vary widely between 45%3 and 83%4 with 24 weeks of
treatment. In addition, the medical costs associated
with the long-term care of these chronic wounds are
substantial.1,2 These difficulties in ulcer management
has raised interest in pharmacological treatment to
promote healing. Selecting an appropriate medication
requires an understanding of the pathological causes
leading to leg ulceration. It has been shown that
inappropriate leucocyte activation is present in
chronic venous disease and that this may be important
as a cause of venous ulceration.ing author. Dr Catherine Lok, MD, PhD, Service de
, Hopital Sud, 80054 Amiens Cedex 1, France.
: lok.catherine@chu-amiens.fr
red as Ardiumw, Alvenorw, Arvenumw 500, Capivenw,
atecw, Flebotropinw, Varitonw, Venitolw.
0198+ 11 $35.00/0 q 2005 Published by Elsevier Ltd.Micronized purified flavonoid fraction (MPFF,
Daflon 500 mgw*, Servier, France), consisting of 90%
diosmin and 10% flavonoids expressed as hesperidin,
has been shown to protect the microcirculation from
damage secondary to raised ambulatory venous
pressure.5 It decreases the interaction between leuco-
cytes and endothelial cells by inhibiting expression of
endothelial intercellular adhesion molecule 1 (ICAM-
1), and vascular cell adhesion molecule (VCAM), as
well as the surface expression of some leucocyte
adhesion molecules (monocyte or neutrophil CD 62
L, CD11B).6 There are few known side effects, and
interactions with other drugs have not been reported.5
In previous trials,5 MPFF used as adjunctive therapy to
compression and appropriate local care demonstrated
promising results on the acceleration of the healing
process. The objective of this meta-analysis was to
quantify the specific effect of MPFF over conventional
treatment in venous leg ulcer healing. An additional
objective of this analysis was to investigate those
clinical situations in which adjunctive MPFF might be
more appropriate.Eur J Vasc Endovasc Surg 30, 198–208 (2005)
doi:10.1016/j.ejvs.2005.04.017, available online at http://www.sciencedirect.com on
Adjunctive Treatment of Venous Leg Ulcer 199Materials and MethodsSearch
Electronic databases were searched, including Med-
line, Embase, and the Cochrane Library (last search
December 2003). All randomised controlled trials
examining the effect of compression alone versus
adjunctive treatment on the healing of venous leg
ulcer were considered, with no restriction on publi-
cation status, date or language.Study selection
Controlled trials of venous leg ulcer healing were
selected with the key words Daflon 500 mg, MPFF, or
flavonoids. The analysis in this report was limited to
investigations with (1) randomised, controlled study
design; (2) inclusion and exclusion criteria clearly
described; (3) an accurate diagnosis of the venous
origin of the ulcer; (4) objective criteria used for the
end-point assessment; and (5) treatments prescribed at
the manufacturer’s recommended dose for MPFF (two
tablets per day). Patients included in these trials had
clinical signs of venous leg ulceration such as
hyperpigmentation, lipodermatosclerosis, and an
ulcer located in the gaiter region. They also had a
previous history of varicose veins or post-thrombotic
syndrome. Patients were investigated by either con-
tinuous wave venous Doppler or by duplex ultra-
sound examination at baseline to confirm the presence
of venous reflux. Reflux duration ofO0.5 s was taken
as evidence of venous valve incompetence. In
addition, continuous wave Doppler or duplex ultra-
sound examination was used to exclude patients with
arterial diseases (ankle brachial index O0.8). The
duration of the current ulcer had to be at least 3
months for inclusion in these trials.
All patients were treated with conventional therapy
combining compression and appropriate local care.
MPFF was given as an adjunctive therapy in all trials.
A minimum compression of 30 mmHg at the ankle
was accepted as appropriate for the management of
leg ulcers. Decisions over inclusion of studies were
made according to predefined items of a checklist for
methodological quality recommended by the
Cochrane Wounds Group (see below).Definition of the meta-analysis end points
Complete ulcer healing after 6 months of treatment
was the main end point of the meta-analysis. Completehealing is the most common end point used.7 It was
defined as complete wound re-epithelialisation. We
chose a 6-month treatment period as this is the
duration of treatment recommended in consensus
documents on venous ulcers,7,8 and is frequently used
for randomised controlled trials for leg ulcers. In
patients with multiple ulcers, the reference ulcer was
that with the largest area.
The secondary end points of this study were time to
healing, as well as the healing rate at intermediate
times (2 and 4 months), and the healing rate according
to ulcer characteristics.Definition of subgroups of patients
The patient database was made available to us by
the manufacturer so that we could stratify analyses
according to the ulcer characteristics of the
patients. This was done according to the prognostic
model previously used to screen patients with a
venous leg ulcer likely to remain unhealed within
24 weeks.9 In validation data sets, ulcers with a
high risk of failure to heal were those larger than
5 cm2 and those that had been present for more
than 6 months. Subgroups were, therefore, defined
according to (i) the ulcer size: !5, 5–10, R10 cm2;
and !10 and R10 cm in the long axis, (ii) the ulcer
duration: !6 months, 6–12 months, and R12
months); and (iii) the time from first ulcer, defined
as the period of time since the onset of the first
ulcer to the time of each trial. This was divided
into patient with duration of disease !5 years or
R5 years.Statistical analysis
The reduction of the relative risk (RRR) and 95%
confidence interval (CI) were calculated for healing
rate for the MPFF treatment group compared to the
standard treatment group. Type 1 error was set at 5%.
Since, the desired treatment effect is increased ulcer
healing, RRR expresses a better chance of an ulcer
healing and, therefore, should be positive to indicate a
benefit of adjunctive MPFF over conventional treat-
ment alone. We did not use an odds ratio calculation
because such calculations are difficult to interpret
clinically. Data were combined by applying the
standard methodology outlined by Whitehead and
Whitehead.10 Assessment of homogeneity between
trials was performed using Cochran Q test.11 Hetero-
geneity was judged significant if the P value was less
than 0.05. Where there was non-homogeneity between
trials, a random effect model was used.11 The overallEur J Vasc Endovasc Surg Vol 30, August 2005
P. Coleridge-Smith et al.200estimated relative risk (RR) was the result of an
exponential transformation of the maximum like-
lihood estimator (MLE) obtained with the model. In
other situations, a fixed effect model was used, and
results were confirmed with a random effect model.11
In cases of heterogeneity, sensitivity was assessed to
determine the effect of sources of variation. The
standard Kaplan–Meier methodology was used to
estimate the probability of healing over time,10 and
homogeneity of the log hazard ratios between trials
was performed using the Cochran Q test.11 The
common hazard ratio was estimated and tested
using the Peto method.11Data management
Information was sought from either the investi-
gators or the manufacturer. Patient databases were
received in an electronic format and extracted for
the analysis by an independent company (IDDI,
Brussels, Belgium). The authors acknowledge that
this meta-analysis was funded by the manufacturer
of MPFF but consider that the use of an indepen-
dent data management company distances the
funding of the study from the objective data
analysis. The data reported here can be considered
as reliable as any study in which data have been
aggregated from a number of different controlled
trials.ResultsDescription of selected trials (Tables 1 and 2)
A total of 15 publications on MPFF in ulcer healing
were identified by the literature search, of which three
were controlled trials.12–14 Four additional unpub-
lished controlled trials were obtained from the
manufacturer’s files.15–18 Seven studies were ident-
ified that met the methodological characteristics
required by the Cochrane Wounds Group (Table 1):
in each trial, inclusion and exclusion criteria were well
defined, the method used for the randomisation was
mentioned, treatment groups were comparable at
baseline for age, gender, and ulcer characteristics.
Reference ulcers were assessed at baseline by their
longest axis (cm) or by planimetry (cm2); sample size
had been calculated a priori in some trials,15–18 and
the number of patients was over 100 in all trials. Of
these studies, four had used blinded assessment of
ulcers.12,15–17 Planimetry assessments had not been
reported at intermediate study times in one study.17 InEur J Vasc Endovasc Surg Vol 30, August 2005another study,16 7% of ulcer data was found to be
missing at baseline, 12.8% of patients displayed major
deviations from the protocol, and 25.4% had been
withdrawn or lost to follow-up. These two trials16,17
were, therefore, excluded, so that five studies were
finally selected12–15,18 as relevant randomised con-
trolled trials (RCT), two of which are unpublished.15,18
Descriptive data of each of the five selected trials
(RCT1 to RCT5) are shown in Table 2.
All five trials had a similar design in that the MPFF
group was compared to a control group. In the MPFF
group, the medication was given at the currently
recommended dose (2!500 mg MPFF per day) for 2
months in RCT112 or 6 months in the others,13–15,18 in
combination with conventional therapy. In RCT112 and
RCT215 patients, the control group received placebo at
the same dose in addition to conventional therapy. In
the three other trials,13,14,18 control subjects received
conventional treatment alone. Local treatment con-
sisted of mechanical cleaning,12–15,18 application of
normal saline and moist pads.12–15,18 Local treatment
varied to some extent depending on the country of the
study: hydrocolloid dressings were used in France,
Germany, and Poland,12,13,15 and silver nitrate solution
was used in Czech Republic,14 while silver sulfadia-
zine and paraffin were used in Russia.18 Compression
was applied to the limbs of all patients using stockings
or bandages to achieve a minimum of 30 mmHg
compression. In RCT2,15 inelastic bandages were used
so that the pressure applied reached 40 mmHg at the
ankle (Table 2).
In one study (RCT5),18 the time to healing was the
primary outcome measure while in the remaining
studies the percentage of patients with complete
ulcer healing was used.12–15 The treatment protocol
was re-evaluated regularly, with assessments carried
out every 2 weeks until month 2 in RCT1,12 or month
3 in RCT2–413–15 and then monthly until month 6.13–
15 Only in one trial (RCT5)18 were visits scheduled
monthly. Compliance with treatment was evaluated
during these visits. Compliance with oral treatment
was considered as satisfactory if 80% of the
theoretical dosage had been taken. Patients who
attended wearing their stockings or with bandages
correctly applied as assessed by the investigators
were considered as compliant with compression.
Reported compliance to oral treatment varied
between 90 and 99% (Table 3). Compliance with
compression was reported in two studies.15–18 It was
88% in each group in RCT215 and two patients (one
in each group) deviated from the protocol for
compression in RCT5.18 All studies were analysed
on an intention-to-treat basis.
Table 1. Randomised controlled trials of micronized purified flavonoid fraction (MPFF) used in combination with conventional treatment for the healing of venous leg ulcers
Trial (date of publication) Inclusion
and exclusion
criteria
Sample size
(arms)
A priori
sample size
calculation
Method of
randomization
Baseline
comparability
of treatment groups
Masking Appropriate
outcome
measures
Intention-to-
treat analysis
RCT1: Guilhou and
colleagues12 (1997)
Yes 107 (2) Not stated Stratified randomiz-
ation according to
the initial ulcer size
Yes Double Yes, planimetry Yes
RCT2*: Rieger/Zuccarelli15 Yes 202 (2) Yes Sealed envelopes Yes Double Yes, planimetry Yes
RCT3: Glinski and
colleagues13 (1999)
Yes 140 (2) Not stated Central randomiz-
ation list
Yes No Yes, planimetry Yes
RCT4: Roztocil and
colleagues14 (2003)
Yes 150 (2) Not stated Not stated Yes, except male
predominance in the
control group
No Yes, planimetry Yes
RCT5*: Saveliev and
colleagues18
Yes 124 (2) No Central randomiz-
ation list
Mean initial ulcer
area larger in the
control group, but
comparable median
size and length in
both groups
No Yes, planimetry Yes
RCT6*: Ming Keng and
colleagues16
Yes 134 (2) Yes Central randomiz-
ation list
Not stated Double Yes Yes
RCT7*: Ulloa and colleagues17 Yes 137 (2) Yes Sealed envelopes Yes Double Yes Yes
RCT, randomised controlled trial.
* Trials without a date of publication are unpublished.
Table 2. Summary of the five trials that met the inclusion criteria
Trial Diagnostic method Intervention Control Outcome
Guilhou and
colleagues12 (RCT1)
Clinical examination and A-V Doppler-
assessed ABIO0.8 and ulcer durationO3
months
MPFF 500 mg, two
tablets per day plus
elastic compression
Placebo plus elastic
compression
Complete healing of the reference ulcer (complete
re-epithelialisation) at 2 months and lifetime analysis
Rieger/Zuccarelli15
(RCT2)
Clinical examination and duplex-
determined venous reflux (ABI O0.9) and
ulcer durationO3 months
MPFF 500 mg, two
tablets per day plus
inelastic two-layer
compression, or
biflex
Placebo plus inelastic
two-layer compression, or
elastic compression
Complete healing of the reference ulcer (i.e. re-
epithelialisation) at each consultation (weeks 2, 4, 6, 8,
10, 12, 16, 20 and 24) and survival analysis
Glinski and
colleagues13 (RCT3)
Clinical examination and Doppler
flowmetry (ABIO0.9) and ulcer duration
O3 months
MPFF 500 mg, two
tablets per day plus
setopress com-
pression bandages
Setopress compression
bandages without pla-
cebo
Complete healing of the reference ulcer at each
consultation (weeks 2, 4, 6, 8, 10, 12, 16, 20 and 24)
Roztocil and
colleagues14 (RCT4)
Clinical examination and ABI O0.9
assessed by A-V Doppler and ulcer
durationO3 months
MPFF 500 mg, two
tablets per day plus
elastic bandage (type
not specified)
Elastic bandage without
placebo
Complete healing of the reference ulcer at each
consultation (weeks 2, 4, 6, 8, 10, 12, 16, 20 and 24) and
time to complete healing
Saveliev and
colleagues18 (RCT5)
Clinical examination and ABI O0.8
assessed by A-V Doppler and ulcer
durationO3 months
MPFF 500 mg, two
tablets per day plus
elastic compression
(type not specified)
Elastic bandage without
placebo
Time to complete healing, rate of patients with
complete healing at 6 months
Trials 15 and 18 are unpublished; ABI, ankle-brachial index; A-V Doppler, continuous wave Doppler ultrasound; MPFF, micronized purified flavonoid fraction; RCT, randomised
controlled trial.
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P. Coleridge-Smith et al.202Patient characteristics at baseline in selected trials (Table 3)Demographics
The average age of the population was 64.7 years
(range: 20–88 years), with a higher proportion of
women than men (58 versus 42%).Description of patients according to the CEAP classification
All patients included in these studies were in CEAP
clinical class C6 from the definition of the entry
criteria. The clinical trials in this meta-analysis did
not include sufficiently detailed investigation with
duplex ultrasonography to be able to report the E, A
and P of CEAP. Duplex ultrasonography was not
universally available at all centres when the study
protocols were designed and the CEAP classification
was not universally implemented at the time.Ulcer characteristics
The mean ulcer length was 4.5 cm (range: 1–14 cm)
and mean ulcer area 10.4 cm2 (range: 1–108 cm2). The
mean duration of current ulcer was 19.6 months
(range: 1–237 months). The average number of ulcers
at inclusion was 1.6.Duration of the ulcer disease
When entering the trials, the patients in this meta-
analysis had had their first ulcer on average 13.5 years
previously (range: 0–58 years).Location of ulcer and reflux
Forty-four percent of patients had bilateral leg ulcers,
one third (32%) had ulcers located on the left limb only,
and 24% on the right leg only. Location of reflux was
reported in 57% of the sample. Of those patients, 39%
had superficial reflux alone, 21% had deep reflux
alone, and 34% had both a superficial and deep venous
abnormalities. In the remaining 6%, the location of
reflux was defined as ‘other’.
For all criteria described above, both groups were
comparable at baseline.Previous treatments (Table 3)
Between 7 and 62.3% of patients had undergone
previous surgery by stripping of the saphenous veins
or by phlebectomy. Sclerotherapy had been performed
in 0–43.2% of patients depending on the trial.Treatment effect in all patients
Results described below are summarized in Table 4.Eur J Vasc Endovasc Surg Vol 30, August 2005Healing rates at 6 months (primary end point)
Four trials which included 616 patients continued for 6
months (RCT2–5).13–15,18 At this time point, 61.3% of
these patients were completely healed in the MPFF
group versus 47.7% in the control group in the naı¨ve
pooling. When the four trials were combined, the RRR
for healing was 32% (CI, 3–70%) in favour of the MPFF
group. Nonetheless, heterogeneity between the groups
of trials was significant (PZ0.014). The combination
was sensitive to exclusion of RCT215 (RRR: 45%; CI,
23–71%). In this study,15 some patients received higher
compression bandages (40 mmHg instead of
30 mmHg for the rest of the sample), but exclusion
from the study of patients wearing high compression
had little impact on the results. On the other hand, the
proportion of small ulcers (!5 cm2) was bigger in
RCT2, compared with the other studies (55 versus
43%), as were ulcers that had been present for less than
6 months at the time of each trial (49 versus 34%).
Heterogeneity recorded at 6 months when all trials
were combined may be due to differences in ulcer
characteristics in RCT2. This was verified by sensi-
tivity tests: exclusion from the combined studies of
patients with ulcers !5 cm2 and of those with ulcers
!6 months raised the chance of ulcer healing to 53%
(CI, 15–103%) and 41% (CI, 9–81%), respectively.
Estimates were homogeneous across studies.
Healing rates at intermediate times
Results at month 2 allowed consideration of one
additional trial (RCT1).12 Therefore, the chance for
ulcer healing in the MPFF group compared to the
controls in these five trials combined (NZ723) was
44% (CI, 7–94%; PZ0.015) and the studies were
homogeneous (Fig. 1). No statistical significance was
reached in the analyses at month 4 (PZ0.07).
Time to healing
The relative hazard of healing was 38% higher in the
MPFF group compared to the control group (CI, 11–
70%). The curve of the cumulative percentage of
patients who had healed their ulcer over time (Fig. 2)
indicates a significantly shorter time to healing in the
MPFF group compared with the control group (16
versus 21 weeks; hazard ratioZ1.33). A strong trend in
favour of MPFF began to emerge by week 8 of
treatment.Treatment effect in patient subgroups
Effect of ulcer size
Ulcers between 5 and 10 cm2 (NZ146) had a 40%
better chance of healing with adjunctive MPFF (RRR:
Table 3. Demographic data in the global population and by trial
All patients MPFF/
control (mean)
RCT112 MPFF/
control
RCT215 MPFF/
control
RCT313 MPFF/
control
RCT414 MPFF/
control
RCT518 MPFF/
control
Age (years) 64.8/64.6 (64.7) 70.5/70.4 68.9/67.4 65.1/65.2 63.3/64.8 54.5/54.4
Gender (female in %) 60/55 (58) 76/62 66/62 26/31 77/57 52/63
BMI (kg/m2) – 26.1/27.7 – 29/30 30/31 –
Presence of VV (%) 71/71 (71) 55/63 46/45 94/96 94/88 –
Presence of PTS (%) 41/40 (41) 55/44 52/54 4/4 51/53 –
Previous stripping or phlebectomy (%) (30.2) 25/32.7 62.3 (global) 7/7 17.6/28 –
Previous sclerotherapy (%) (19.3) 28.8/30.9 43.2 (global) 0/0 4.4/3.7 –
Type of reflux (%)
Superficial 38/39 (39) 42/33 37/43 – – –
Deep 21/20 (21) 25/23 19/19 – – –
SuperficialCdeep 32/36 (34) 31/40 32/34 – – –
Localization of the disease
Right (%) 24/24 (24) 15/20 17/21 31/26 21/23 37/29
Left (%) 32/31 (32) 31/22 33/26 34/36 20/24 47/50
Both (%) 44/45 (44) 54/59 50/53 35/38 60/53 16/21
Duration of CVD (years) 24.4/23.4 (24.0) 23.9/23.4 32.3/30.5 21.9/21.1 21.9/22.5 19/20
Time from first ulcer (years) 13.3/13.7 (13.5) 15.8/15.6 17.1/19.0 14.6/13.0 12.5/11.2 4.5/7.5
Duration of the reference ulcer (months) 17.5/21.8 (19.6) – 12/22 29/26 17/17 11/15
Ankle/arm systolic ratio 1.1/1.1 (1.1) 1.1/1.1 1.1/1.1 1.1/1.1 1.1/1.1 1.1/1.1
Mean length of ulcer of reference (cm) 4.54/4.5 (4.5) 5.3/5.5 4.1/4.1 5.5/6.0 4.2/4.1 3.4/3.7
Mean surface of ulcer of reference (cm2) 9.7/11.2 (10.4) 18.0/19.2 7.0/7.6 12.0/15.5 9.0/8.7 4.8/8.0
Mean number of ulcers 1.6/1.6 (1.6) 1.7/1.9 1.8/1.7 – – 1.2/1.2
Wearing of compression
30 mmHg (%) 85/87 100/100 56/66 100/100 100/100 100/100
40 mmHg (%) 15/13 44/34
Compliance to oral treatment O90% 98–99% 99% 99% 97.6%
Compliance to compression – 88%/88% – – 2 pts with protocol
deviation
Abbreviations: BMI, body mass index; CVD, chronic venous disease; MPFF, micronized purified flavonoid fraction; PTS, post-thrombotic syndrome; RCT, randomised controlled trial;
VV, varicose veins; pts, patients.
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Table 4. Reduction of the relative risk of ulcer healing at 6 months in trials comparing the micronized purified flavonoid fraction (MPFF)
group with the control group and percentage of ulcers healed in each group
Sub-group of ulcers Number (N)
at month 6
Percentage of ulcers healed
(naı¨ve pooling) in
RRR
(%)
95% CI
(%)
Test of
treatment effect,
P value
Test of
heterogeneity,
P value
Control group MPFF group
All ulcers 616 47.6 61.3 32 3–70 0.03 0.014
Explanation of the heterogeneity of studies
All ulcers except
those from RCT2
414 44.2 66 45 23–71 !0.001 NS
All ulcers except
those with com-
pressionR40 mmHg
in RCT2
550 48.1 62.8 31 13–71 0.047 0.016
All ulcers except
those!5 cm2
319 30.3 46.9 53 15–103 0.0035 NS
All ulcers except
those!6 mo
337 35.3 49.1 41 9–81 0.008 NS
According to ulcer size
!5 cm2 297 66.4 76.6 18 (K6)–60 NS 0.016
R10 cm2 220 20.7 33.7 NS* NS*
Between 5 and
10 cm2
146 42.6 61.5 40 6–87 0.019 NS
!10 cm2 442 58.5 71.5 25 2–54 0.035 0.026
!10 cm in long axis 609 47.6 62 33 4–69 0.021 0.021
According to ulcer duration
!6 mo 279 62.6 75.8 23 (K6)–60 NS 0.024
R12 mo 201 30 42 40 (K7)–109 NS NS
Between 6 and 12
mo
136 44 59.7 44 6–97 0.021 NS
!12 mo 415 57 70 26 (K1)–62 NS 0.01
According to time from first ulcer
!5 years 164 56 82 36 12–67 0.0023 NS
Abbreviations: mo, months; RCT, randomised controlled trial; RRR, reduction of the relative risk; CI, confidence interval; NS, non-significant.
* Based on odds ratio calculation.
                    
              
              
              
              
              
Fig. 1. Reduction of the relative risk of ulcer healing at 2 months in trials comparing micronized purified flavonoid fraction
(MPFF) with control. O, observed number of healed patients; N, total number of patients; E, expected number of healed
patients; V, variance; CI, confidence interval.
P. Coleridge-Smith et al.204
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Fig. 2. Life-table analysis with cumulative percentage of patients in whom the ulcer healed completely. Comparison in
cumulative healing rates between the micronized purified flavonoid fraction group (solid line) and the control group (broken
line). Median time to healing: MPFF, 16.14 weeks; control, 21.30 weeks. Hazard ratio, 1.33.
Adjunctive Treatment of Venous Leg Ulcer 20540%; CI, 6–87%; PZ0.019). No heterogeneity was
found in this subgroup. As a whole, the 609
participants with ulcers less than 10 cm in diameter
(NZ609) and those with an ulcer below 10 cm2 (NZ
442) had, respectively, a 33% (CI, 4–69%) and 25% (CI,
2–54%) better chance of healing with adjunctive MPFF.
In contrast, no significant effect of MPFF over standard
treatment was shown for ulcers larger than 10 cm2 or
smaller than 5 cm2.
Effect of ulcer duration
In patients with an ulcer that had been present
between 6 and 12 months (NZ136), the RRR of healing
was 44% (CI, 6–97%), and studies were homogeneous.
For those patients who had had an ulcer for less than
12 months (NZ415), the RRR of healing was 26% but
results did not reach significance in this subgroup (CI,
1–62%; PZ0.06). No significant MPFF effect over
standard treatment was found for ulcers of shorter
duration (!6 months), or for the most long lasting
ones (R12 months).
According to the time from first ulcer (duration of the ulcer
disease)
Of the 723 participants, in 520 the duration of their
ulcer disease had been recorded. A total of 164
participants had had their first ulcer episode for less
than 5 years. In this subgroup of patients, the chance ofhealing their ulcer at month 6 was better in the MPFF
group (RRR: 36%; CI, 12–67%). In the remaining
patients in whom ulcer disease had persisted for
more than 5 years, results were not significant.
According to the location of reflux
It was not possible to establish whether patients with
superficial venous reflux alone fared any better than
those with a combination of deep and superficial
venous reflux. The data concerning this distinction
was not recorded and not reliably established in many
centres involved in the studies that did not have
duplex ultrasonography available to them.
Effect of post-thrombotic syndrome
The RRR of healing at 6 months was 47% (CI, 14–90%)
in patients reporting a previous history of venous
thrombosis in the lower limb (NZ236 at month 6), and
the studies were homogeneous. Nevertheless, the
presence of post-thrombotic syndrome was not sys-
tematically verified by duplex ultrasonography in
these trials so these findings must be regarded
cautiously.Discussion
This meta-analysis confirms that MPFF as adjunctiveEur J Vasc Endovasc Surg Vol 30, August 2005
P. Coleridge-Smith et al.206therapy to good local wound care and compression
therapy has a favourable effect on the healing process
within 6 months, with a 32% better chance of patients
healing the ulcer and a healing process shortened by 5
weeks. The aim of this meta-analysis was to answer a
specific question concerning the value of oral MPFF
treatment in the management of venous leg ulcers. The
authors acknowledge that in many cases venous
ulceration may be partially or totally attributable to
superficial venous incompetence. Surgery to saphe-
nous trunks and varices has been shown to be effective
in the management of venous ulceration. In particular,
ulcer recurrence has been prevented in patients with
superficial venous insufficiency (SVI) and in those
with combined segmental deep venous reflux and
SVI.19–21 Surgical treatments such as ulcer excision by
‘shave therapy’ and mesh grafting may also favour
ulcer healing.22 A limitation of the surgical approach is
that some elderly and frail patients may be medically
unfit for treatment or unwilling to undergo invasive
management of their venous disease.
Systemic medications have been used in addition to
standard treatments because of a theoretical ability to
address one or more of the factors that have been
identified in the pathophysiology of venous ulcera-
tion. A small number of drugs have been used with
varying success. Stanozolol, a fibrinolytic anabolic
steroid was expected to break down pericapillary
fibrin cuffs23 but did not increase the rate of ulcer
healing.2 Abnormalities of coagulation observed in
patients with venous disease, have been improved by
the use of aspirin.24 In contrast, a thromboxane
receptor antagonist (ifetroban) failed to show benefit
over compression therapy in ulcer healing.2
Among phlebotropic drugs, the use of horse chest-
nut seed extract25 and of hydroxyrutosides2 resulted in
a reduction in both oedema and symptoms of chronic
venous insufficiency, but failed to demonstrate super-
iority over compression in advanced chronic venous
insufficiency26 or in preventing venous ulcer recur-
rence.27 These findings may be because reduction in
oedema alone is insufficient to treat leg ulceration. The
involvement of growth factors28 and leucocytes6 in the
development of venous ulceration has opened up new
areas of investigation.
In a review of eight clinical trials, pentoxifylline
improved venous ulcer healing on its own and when
used in combination with compression compared with
placebo.29 Pentoxifylline is thought to work by
reducing leucocyte adhesion to the vascular endo-
thelium and through its anti-thrombotic effects. The
way in which MPFF speeds ulcer healing might be by
modulating leucocyte-L-selectin interaction with
endothelial selectins responsible for the initial stagesEur J Vasc Endovasc Surg Vol 30, August 2005of adhesion. By reducing the likelihood of leucocyte
adhesion, MPFF presumably acts through an anti-
inflammatory mechanism.6 Thus, among the many
mechanisms at work in the pathogenesis of venous
ulceration, the mechanism involving leucocyte acti-
vation and interaction with the endothelium seems to
be the one most responsive to pharmacological
treatment up to now. The Kaplan–Meier curve (Fig.
2) shows that a trend in favour of MPFF began to
emerge by week 8. This is comparable with the
findings by Dale et al.30 in which differences in healing
rates between pentoxifylline and placebo were clear
after the first 8 weeks of treatment. Eight weeks might
be the period of time sufficient to influence the
underlying microcirculatory abnormalities.
The rate of complete ulcer healing in the entire
patient group included in our meta-analysis after 6
months is 55%. Previous studies in which compression
alone has been used report complete healing rates of
between 30 and 83% after 24 weeks of treatment.3,4,31,32
The best healing rates come from trials performed in
leg ulcer clinics with nurse specialists working under
medical supervision4,31,32 and the lowest rates from
studies performed outside ulcer-oriented clinics.3,32
Patients included in this meta-analysis were from a
number of countries in which ulcers were treated in
outpatient settings of specialized departments with a
specific approaches to ulcer care. Healing rates in this
analysis are within the range of those published from
other centres. Compression applied in trials of this
analysis was 30 mmHg at the ankle, judged by
investigators to be the pressure most suitable for
patient compliance and daily convenience. This most
probably reflects the way in which compression is
applied in daily practice.
In prognostic models,9 ulcers exceeding 5 cm2 and
those persisting for more than 6 months are slower to
heal with conventional therapy. Information regarding
ulcer size is not always reported in published clinical
trials on leg ulcer healing, making direct comparison
difficult. The mean wound size in our meta-analysis
(10.4 cm2) falls within the range where ulcers might be
slow to heal.9 Ulcer duration has been reported in the
range 1–9 months in recent publications.3,4,32 The
study group in our meta-analysis had mean ulcer
duration of 19.6 months that also might adversely
affect the rate of healing. The entry criteria for studies
included in the meta-analysis required ulcers which
had been present for longer than 3 months in order to
avoid wounds of traumatic origin that usually heal
rapidly. The duration of venous disease is probably a
further important factor determining ulcer healing,
though its assessment depends upon patients’ mem-
ory of events. The duration of ulcer disease (average
Adjunctive Treatment of Venous Leg Ulcer 20713.5 years) was recorded in 98% of our sample. This
information is missing from many published clinical
trials on leg ulcer healing.
Our results suggest that MPFF gives additional
benefit to conventional therapy in ulcers between 5
and 10 cm2 and those present for 6 to 12 months. No
additional MPFF effect was shown in ulcers limited in
size (!5 cm2) nor duration !6 months. This may be
because compression treatment alone is all that is
required in treating small ulcers of short duration.
MPFF seems to be most appropriate when the venous
ulcer disease has been present for less than 5 years.
None of the studies included in this analysis
addressed the recurrence rate following healing. This
is clearly an important point since recurrence of ulcers
following healing is a common problem and contrib-
utes greatly to the cost of management of patients with
leg ulcers. A prospective long-term study using
adjunctive MPFF in patients with healed leg ulcers
would be needed to answer this question. No such
study has so far been performed.
In conclusion, we have found that oral treatment
with MPFF in addition to standard compression
treatment and woundmanagement accelerates venous
leg ulcer healing. No benefit was found in smaller
ulcers of short duration (!6 months) that would in
any case be expected to heal easily. Larger ulcers (5–
10 cm2) of 6–12 months duration were found to benefit
most from MPFF treatment. These ulcers tend to heal
more slowly and an adjunctive treatment may be of
advantage in such circumstances.Acknowledgements
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